Summary Using a highly discriminatory DNA typing technique, based on the polymerase chain reaction and reverse dot blot hybridization, more refined results were obtained on the association of particular HLA class II alleles, haplotypes and genotypes with insulin-dependent diabetes mellitus in the Belgian population. The previously reported predisposing effect for the DRBI*0301 encoded DR3 serologic specificity was confirmed and could be assigned to the DRB3*0200 encoded DR52b serologic specificity. A second high risk haplotype, DRBI*0401-DQBI*0302 encoding the DR4-DQ8 serologic specificity, accounted for increased susceptibility both in the total insulin-dependent diabetic population and among DR4-positive patients. Moreover, we found that these DR4 associated DRB1 and DQB1 alleles act as independent risk factors. A possible role for the DPB1 locus can be rejected since the observed predisposing effect for DPBI*0202 probably occurred due to linkage disequilibrium of this allele with DRBI*0301. Particular extended haplotypes accounted for the decreased relative risk observed for the DR2, DR11 and DR13 serologic specificities. The highest relative risk was observed for those DQA1/DQB1 genotypes, allowing for the formation of 4SS (DQ0~Arg52+/DQflAsp57-) heterodimers. [Diabetologia (1994) 37: 808-817] Key words Insulin-dependent diabetes mellitus, HLA, class II, PCR, SSO typing.
Summary Using a highly discriminatory DNA typing technique, based on the polymerase chain reaction and reverse dot blot hybridization, more refined results were obtained on the association of particular HLA class II alleles, haplotypes and genotypes with insulin-dependent diabetes mellitus in the Belgian population. The previously reported predisposing effect for the DRBI*0301 encoded DR3 serologic specificity was confirmed and could be assigned to the DRB3*0200 encoded DR52b serologic specificity. A second high risk haplotype, DRBI*0401-DQBI*0302 encoding the DR4-DQ8 serologic specificity, accounted for increased susceptibility both in the total insulin-dependent diabetic population and among DR4-positive patients. Moreover, we found that these DR4 associated DRB1 and DQB1 alleles act as independent risk factors. A possible role for the DPB1 locus can be rejected since the observed predisposing effect for DPBI*0202 probably occurred due to linkage disequilibrium of this allele with DRBI*0301. Particular extended haplotypes accounted for the decreased relative risk observed for the DR2, DR11 and DR13 serologic specificities. The highest relative risk was observed for those DQA1/DQB1 genotypes, allowing for the formation of 4SS
HLA genes are encoded in the human MHC complex on chromosome 6p21.3. Strong linkage disequilibrium exists within this complex of genes but rare recombination events during evolution gave rise to different HLA haplotypes in different ethnic groups [3] [4] [5] . Among Caucasians, HLA class II DR3 and DR4 alleles are positively associated with IDDM, while DR2 alleles have been shown to confer protection to the development of the disease [2] . A stronger association with homozygosity for particular DQB1 alleles encoding an aa other than Asp at position 57 was originally found by Todd et al. [6] and confirmed in other studies [7, 8] . Since then, interest has focused on the DQ subregion and a stronger association was found when both DQB1 and DQA1 loci were examined [9] . Characteristically, DQA1 alleles conferring susceptibility encode Arg at aa position 52. Khalil et al. [10] demonstrated that rather the combined presence of DQfl Asp57-(S) and DQ(z Arg52+ (S) alleles confer the highest risk of developing IDDM. A model was pro-posed suggesting a dose effect for the number of susceptible DQc~I3 (SS) heterodimers, encoded in cis or tr ans [11] .
In this study 211 IDDM patients and 205 healthy control subjects, all Caucasians from Belgian origin, were typed for the DRB1, DRB3, DRB4, DRB5, DQA1, DQB1 and DPB1 alleles, using a previously described rapid and non-isotopic SSO typing assay, based on the PCR and reverse dot blot hybridization [12] . We evaluated a possible association of the class II alleles and their extended haplotypes and genotypes with IDDM.
Materials and methods

Patients and controlsub]ects.
Blood from a total of 211 unrelated IDDM patients, all Caucasians of Belgian origin was collected at the paediatric and adult endocrinology units of the University Hospital of Leuven. All children and adolescents had typical clinical IDDM, while in adults IDDM was confirmed by very low C-peptide levels after glucagon administration (maximum < 0.1 mmol/1) or by the presence of anti-islet auto-antibodies. Eighty-nine patients were female and 122 were male; the mean age at disease onset was 16.5 years (range 1-53 years). Our control population consisted of 205 healthy blood donors, all Caucasians of Belgian origin. They were collected from the Blood Transfusion Center of Leuven and had no personal or family history of IDDM.
PCR amplification and SSO typing. All patients and control subjects were typed for the DQA1, DQB1, DPB1, DRB1, DRB3, DRB4 and DRB5 alleles as described previously [12] . Briefly, the polymorphic second exons of the DQA, DQB, DPB, DRB genes were amplified by the PCR and subsequently hybridized to a total of 11 DQA1,18 DQB 1,23 DPB1 and 31 DRB SSOs using a rapid and non-isotopic reverse dot blot hybridization assay. A DR4-DRBlgroup-specific amplification andhybridizationwas alsoincluded to increase the resolution for particular DRBl*04 homoor heterozygous persons. The originally described DRB and DPB 1 hybridization protocols were adapted to yield a reverse hybridization assay on membrane-based strips with SSOs immobilized in a line-wise fashion and the initially described chemiluminescence detection protocol was adapted to yield a colorimetric visualization of positive hybridization signals, using the NBT/BCIP substrates (hmogenetics N. V., Gent, Belgium).
For the DQA1 gene, at the time we started this study the DQAl*0302 and D QAl*0104 alleles had not yet been described and therefore the DQAl*010110104 and DQAl*030110302 alleles could not be distinguished and were grouped in this study as DQAI*0101 and DQA1 "0301, respectively. For the DQB 1 gene, the recently described D QB 1"0606 allele [13] could not be distinguished from DQBI*0605. The recently defined DQB1*0304 [14] , DPBl*2201 [15] , DPBl*2301 [16] , DRBI*0303 [17] , DRBI*1409 and DRBl*1410 [16, 18] alleles were each unambiguously defined by a unique combination of SSOs and could therefore be included in this study. For the DRB locus, the DRBl*1501/1503 and DRB1*1601/1602 alleles were not distinguished by our combination of SSOs and were grouped as DRBl*1501 and DRBI*1601, respectively. Because typing of the four expressed DRB genes is done simultaneously, combinations of alleles differing only at aa position 86 could not be distinguished. Therefore, the alleles DRBl*1501/ 1502, DRBl*030210303, DRBl*1101/1104, DRBl*1301/-1302, DRBl*1401/1407, DRBl*140211406, DRBl*0801/0805, 809 DRB3*0201/0202 were grouped as DRBl*1500, DRBI*0302, DRBl*1101, DRB1*1301, DRB1*1401, DRBl*1402, DRB 1"0801 and DRB3*0200, respectively.
A DRB1 locus-specific PCR, amplifying all DRB1 alleles except the DR2, DR7 and DR9 groups, was achieved using the previously described DRB1 primer CRX37 (5'-GAATTCCCGCGCCGCGCT-3') [19] , matching a unique DRB 1 sequence in the intron 3' of exon 2, in combination with the conserved DRB-1 primer (5'-GATCCTrCGTGTCCCCA-CAGCACG-3') used in our assay for the co-amplification of the four DRB genes [12] . Genomic DNA (0.5 gg) or 2.5 gl of a lysed blood sample was amplified in a total volume of 50 gl containing 50 mmol/l KC1, 10 mmol/1 Tris-HC1 (pH 8.3), 0.01% gelatin, 1.5 retool/1 Mg 2+, 200 gmol/1 of each dATR dCTR dGTP (Pharmacia LKB Biotechnology, Uppsala, Sweden), 180 gmol/1 of dTrP (Pharmacia LKB Biotechnology, Uppsala, Sweden), 20 gmol/1 of biotin-ll-dUTP (Sigma Chemical Company, St. Louis, Mo., USA), 0.2 gmol/1 of each primer and 0.5 unit of Thermus aquaticus DNA polymerase (Perkin-Elmer Cetus Corp., Norwalk, Conn., USA). The amplification was carried out on a DNA Thermal Cycler (Perkin-Elmer Cetus Corp). An initial denaturation step of 5 min at 95 ~ was followed by 32 cycles of incubation for 1 rain at 95 ~ 1 min at 55 ~ 1 min at 72 ~ A final extension step of 10 min at 72 ~ added. In our study this DRB1 typing was used to discriminate the DRBl*0802/DRB 1"0804 alleles and the DRBI*0301/DRB1*0302/DRBl*0303 alleles for heterozygotes carrying the DRB3*0301 allele. A DR2-DRB1 group-specific amplification was developed using the DR2-DRB1 primer (5'-TTCCTGTGGCAGCCTAAGAGG-3') of the 11 th International Histocompatibility Workshop, matching the unique DRB1 sequence that characterizes the DR2 alleles, in combination with the conserved DRB-2 primer (5'-GCCGCTGCACTGTGAAGCTCTC-3') used in our assay for the coamplificationofthe four DRB genes [12] . The amplification mixture and PCR conditions were identical to the DRB1 locusspecific amplification except for Taq polymerase, used in a concentration of i unit/50 gl amplification mixture. This DR2 groupspecific analysis was performed in our study to analyse the DRB1 alleles in DR2 homozygotes and particular DR2 heterozygotes.
Statistical analysis. RR is an odds ratio: (number of patients with allele/number of patients without allele)/(number of control subjects with allele/number of control subjects without allele) [20] . P-values were calculated by the Fisher Exact Test [21] and corrected for the number of tests carried out by the use of the Bonferoni correction [22, 23] . RRs were calculated for different alleles, haplotypes and genotypes. In the analysis of the alleles and haplotypes, we assume that individual alleles and haplotypes at a given locus constitute independent risk factors. RRs and p-values were only calculated for those alleles or haplotypes that were counted at least 10 times in the total (control + IDDM) population.
In each group of control subjects and IDDM patients, DQA1-DQB1-DRB1 haplotypes were deduced from subjects who were homozygous for at least two of three loci. The obtained results fitted with those expected from the reported linkage disequilibria [4, 24] , except for two previously undescribed haplotypes. DRB1-DRB3 haplotypes were deduced from DRB1 (DRB3 associated) or DRB3 homozygotes and from DRB3/non-DRB3 heterozygotes. An analogous strategy was followed to deduce the DRB1-DRB5 haplotypes. No DRB1-DRB3 or DRB 1-DRB5 haplotypes that did not follow the established linkage disequilibrium were found [4] .
Differences in RRs within groups of alleles were calculated via a likelihood ratio test. In this approach, two likelihoods are calculated on the observed data: the first likelihood is calculated under the assumption that all alleles of a given group convey the Fig. 1 . Examples of DRB1 locus-specific typing results. DNA of four heterozygous subjects was amplified for the DRB (A, B, C, D) or DRB1 (A', B', C', D') genes, using the DRB-1/DRB-2 (12) or DRB-1/CRX37 primer pairs, respectively. PCR products were subsequently hybridized to a number of membrane-bound locusspecific SSOs. Positive hybridization signals were visualized using a colorimetric (NBT/BCIP based) detection reaction same RR, while the second likelihood is calculated under the assumption that each allele within that group confers a specific RR, which may be different from the RR of the other alleles. By taking twice the difference of the natural logarithms of these likelihoods, one obtains a statistic that will approximately follow a chi-square distribution, with the appropriate number of dr.
When a high-or low-risk allele was identified, we subsequently analysed the possibility of subdividing that risk allele more accurately by comparing the risks for two-locus haplotypes containing that particular allele. The statistical evaluation involved a chi-square test with the appropriate number of dr. While this method allows the definition of high-and low-risk haplotypes, it does not distinguish between the effects due to linkage disequilibrium between the loci and the effects due to independently acting risk alleles that occur together in a haplotype. To make such distinctions, we applied a stepwise likelihood-ratio test. The following scenarios were evaluated: i) neither allele in the haplotype conveys any risk (HO), ii) only an allele at one of the loci conveys risk, there is no disequilibrium between the loci (one extra dfover HO), iii) both loci convey risk, but they are not in linkage disequilibrium (the alleles constitute independent risk factors) (two extra df over HO), iv) an allele at one of the loci conveys risk, the other allele is not a separate risk factor, but is in linkage disequilibrium with the first allele (two extra df over HO) and v) both loci convey risk, and they are in linkage disequilibrium with each other (four extra drover HO).
Fig.2.
Examples ofDR4-DRB1 andDR2-DRB1 group-specific typing results. DNA of two heterozygous subjects was amplified for the DRB (A, B) and DR4-DRB1 (A') or DR2-DRB1 (B') genes, using the DRB-1/DRB-2 and DR4-1/DRB-2 or DR2-DRB1/DRB-2 primer pairs, respectively. PCR products were subsequently hybridized to a number of membrane-bound locus-specific SSOs. Positive hybridization signals were visualized using a colorimetric (NBT/BCIP based) detection reaction. DR2 ~ for DR2 homozygote subjects, the presence or a] Ic lic identity of the DRB1 genes cannot be detected using the DRB typing protocol
ResuRs
DRB1 locus-specific and DR2-DRB1 group-specific analysis. In our initial assay [12] , all four expressed D R B genes were amplified and t y p e d together. This allows for a very rapid and simple analysis but c o m p l e t e subtyping b e c o m e s impossible for particular heterozygotes, encoding D R B 1 alleles that differ only at aa position 86. Also, no discrimination could be m a d e b e t w e e n the D R B I * 0 3 alleles for persons carrying the DRB3*0301 allele. To allow for further analysis of these allelic combinations, we developed a D R B 1-specific P C R . This additional analysis was applied to discriminate the The alleles DQAI*0401/0601 could not be distinguished in one control subject and two IDDM patients, encoding DQAI*0201 on the second chromosome. For these subjects, only the DQAl*0201 allele was included in the statistical analysis. Therefore, a total of 420 diabetic and 409 normal chromosomes were compared. All DQA1 alleles that were not counted at least 10 times in the total (control + IDDM) population were not tested. p-values were corrected for the number of DQA1 alleles tested. n: Number of IDDM patients and control subjects; a: Number of diabetic and control chromosomes. N.T.: not tested, N.S.: not significant Distribution of DQA1 alleles. As described previously [10] , alleles encoding Arg 52+ DQa chains are susceptibility alleles (Table 1) . A statistical test was carried out to evaluate whether there is a significant heterogeneity among the RRs of the various alleles encoding Arg 52 positivity. The result yielded a chi-square value of 21.04 (2 df), which implies that homogeneity of risks within the Arg 52+ group could be rejected with a p-value of 0.00003. Among IDDM patients, the frequencies of the DQAI*0301 (Arg 52+) and the DQAI*0102, DQAI*0103, DQAI*0201 (Arg 52-) alleles were significantly increased and decreased, respectively.
Distribution ofD QB1 alleles. The distribution of the 16 DQB1 alleles defined in this study is shown in Table 2 .
As described previously [6--8] , alleles encoding Asp 57-DQfl chains are susceptibility alleles (Table 2) . Homogeneity among the RRs of the various alleles within the Asp 57-group could be rejected with a chi-square of 52.20 (4 dr), corresponding to a p-value less than 10 ~. Among IDDM patients, the frequencies of the DQBI*0201, DQBI*0302 (Asp 57-) and the DQBI* 0301, DQBI*0602, DQBI*0603 (Asp 57+) alleles were significantly increased and decreased, respectively.
Distribution of DPB1 alleles. Unresolved typing results
were obtained for a total of four control subjects who were not included in the statistical analysis. The same was true for a previously undefined DPB1*4601 allele that we detected in one control subject [28] . The DPBI*0401 was the most frequent allele in the two populations. A significant increase (RR=16.66, p = 0.0012) of the rare DPBI*0202 allele in the IDDM patient population was found. In general, DPB1 alleles are not in linkage disequilibrium with DRB or DQA/DQB alleles. However, the increased risk conferred by DPB 1"0202 seems to be secondary to linkage disequilibrium with the increased DRB1*0301 allele in the IDDM population. Indeed all 17 IDDM patients carrying a DPBI*0202 allele were DRBI*0301 positive, although this does not mean that the two alleles were encoded on the same chromosome. However, 11 of 17 were DRBI*0301 homozygous and therefore at least 64.7 % (in contrast to the 11.9 % expected from the allele frequency of DRB1 "0301) of the DPB 1 *0202 alleles were associated with the DRBI*0301 allele, clearly indicating a non-random association between these two alleles. The one DPB 1"0202 positive control subject was DRBI*0301 negative.
Distribution of DRB alleles. The distribution of the 33 DRB1 and 3 DRB5 alleles defined in this study is shown in Table 3 . Unresolved typing results (DRBl*0405/0408 = DRB1*0405/0405, DRBI*0401/ 0405 = DRB1*0408/0409, DRBl*1201/DRB1*0101-DRB1*0102) were obtained for three IDDM patients and one control subject and were not included in the statistical analysis. The DRBl*1101/DRBl*1102 and DRBl*1301/DRBl*1305 alleles were pooled as DRBl*1100 and DRB1*1300, respectively and these groups of alleles were compared as such between the two populations. Because a similar protective effect was observed for the individual alleles that were pooled in the two groups and because the frequencies of DRB1*1102 and DRB1*1305 were low (data not shown), it is unlikely that this had any influence on the outcome of the analysis. Because no significant effects were observed for the different DR4 alleles, except for DRBl*0401, and because the frequencies of the individual alleles were rather low (data not shown), we decided to pool all DRBI*04 subtypes, except for DRB1*0401 (defined as DRB1*0400) and to analyse them separately from DRB 1"0401. Among IDDM patients, the frequency of the DRB1*0301 and DRB1*0401 alleles was significantly increased. A significant decrease of the DRB1*1500, DRB1*0701, DRB1*1100 (mainly caused by DRB1*1101, data not shown), DRB1*1300 (mainly caused by DRBl*1301, data not shown) alleles was also seen.
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Comparison of DRB3 alleles revealed no significant association with IDDM. Thus, we analysed whether particular high or low risk DRB1 associations could be further defined by considering the DRB1-DRB3 haplotypes. Therefore, the DRB1-DRB3 haplotypes for those DRB 1 alleles that were in linkage disequilibrium with more than one DRB3 allele (DRB1*0301 and DRBI*1300) were compared ( Table 4) . Subdivision of the DRBl*0301 haplotype into a DRB3*0101 and a DRB3*0200 group showed an increase of the DRBl*0301-DRB3*0200 haplotype in the IDDM group. It should be mentioned that RRs differ from those presented in Table 3 . Here, the RRs were calculated by comparison with the non-DRBl*0301 group. Homogeneity among the RRs for the different DRBl*0301-DRB3 haplotypes within the DR3 group could be rejected with a chi-square of 19.30 (1 dr), corresponding to ap-value of 0.000011. Thus, although a susceptibility role for DRBI*0301 was found in the Caucasian population by several groups [2, 29, 30] , this effect could be further defined by analysing DRB1-DRB3 extended haplotypes for this allele. Analogously, we analysed if the protective effect of DRBI*1300 could be further defined by considering the DRB1-DRB3 extended haplotypes. For the DRB1*1300 alleles, the DRB3*0101 associated haplotype was significantly decreased in the IDDM patient population (data not shown). Again, RRs differ from those presented in Table 3 , as they were calculated by comparison with the non-DRB1*1300 group. Homogeneity among the RR for the different DRB 1*1300-DRB3 haplotypes within the DRBl*1300 group could be rejected with a chisquare of 9.701 (2 dr), corresponding to a p-value of 0.0078. The situation is more complex however, because of the existing linkage disequilibrium of the DRB 1" 1300 alleles with different neutral or protective DQA1-DQB1 haplotypes (see below).
Analogous analysis of the DRB5 alleles (Table 3) showed a significant decrease, to the same extent as DRBl*1500, of DRB5*0101, among IDDM patients. This is a consequence of the strong linkage disequilibrium between the DRB5*0101 and DRBI*1501 alleles [4, 24] .
Distribution of DQA1-DQB1-DRB1 haplotypes.
The distribution of the 33 deduced DQA1-DQB1-DRB1 haplotypes found in this study is shown in Table 5 . Deduced haplotypes fitted with those expected from the reported linkage disequilibria [4, 24] for all except one control subject and one IDDM patient. A significant decrease of the DRB1*1500-DQAl*0102-DQB1* 0602, DRBl*1100-DQAl*0501-DQBl*0301, DRBI* 1300-DQAI*0103-DQBI*0603, DRBI*0701-DQAI* 0201-DQBl*0303 haplotypes in the IDDM patient population was shown. The DRB1*0301-DQAl*0501-DQBl*0201 and DRBI*0401-DQAI*0301-DQBI* 0302 haplotypes were however significantly increased among the diabetic patients. P-values were corrected for the number of DRB1 and DRB5 alleles tested. The DRBI*0400 group contains all DRBI*04 alleles except for DRB 1"0401. The DRB 1"1100 and DRBl*1300 groups contain the DRBl*1101/1102 and DRBl*1301/1305 alleles, respectively. All DRB alleles that were not counted at least 10 times in the total (control + IDDM) population were not tested. Unresolved typing results (DRB1*0405/0408= DRBl*0405/0405, DRBl*0401/0405 = DRB1*0408/0409, DRB1*1201/DRB1*0101-DRBl*0102) were obtained for three IDDM patients and one control subject and were not included in the statistical analysis, a: number of diabetic and control chromosomes. N. S., not significant All diabetic and control subjects who carry the DRB1*1500-DQA1*0102-DQB1*0602 haplotype encode the DRB5*0101 allele. In our assay we could not distinguish between the DRB 1" 1501/1502/1503 alleles. However, because of the reported linkage disequilibria for the DR2 alleles [4, 24] , it is most likely that DRB1*1501 is present in this strong protective haplotype. Although DRBl*1501/1503 are both included in identical extended haplotypes, DRB1*1503 can probably be excluded because it is almost exclusively found in the black population [4, 31] . It is also unlikely that the DRBl*1500 haplotype contains DRB1*1502 because this allele is probably included in the DRB5*0102 encoding DRBl*1500-DQA1*0103-DQBl*0602 and DRB l*1501-DQAl*0102-DQB 1"0502 haplotypes, predominantly present in the orientalpopulation [4, 24] .
By subdividing the DRB1*1300 group according to the extended DQA1-DQB 1 haplotypes, the protective effect of DRBl*1300 seems to be mainly caused by the DQA1*0103-DQBl*0603 haplotype {RR for DRBI*1300= 0.394 (Table 3) , RR for DRB1*1300-DQA1*0103-DQB1*0603=0.176 (Table5)}. In accordance with the reported linkage disequilibrium [4] , the DRB1*1300-DQAl*0103-DQBl*0603 haplotype was exclusively associated with the expression of the DRB3*0101 and DRB3*0200 alleles in our population. We concluded that the protective effect of the DRB1*1300-DQAl*0103-DQBl*0603 haplotype is strictly related to the expression of DRB3*0101 (data not shown). This is similar to what we observed for DRBI*0301, where susceptibility was related to the expression of DRB3*0200. These results for the DRBl*1300 haplotype allow us to suggest that DRB1*1301, rather than the DRBl*1302 or the DRB1*1305 alleles will be included in this protective haplotype. Although we can suggest the DRBl*1501 and DRBl*1301 alleles are responsible for the protective effect of the DRBI*1501 and DRBI*1300 groups of alleles, it should be mentioned that minor exceptions to the accepted linkage disequilibria have been reported [4, 24] .
Interesting also is the DRB 1"07 haplotype; whereas the DQA1*0201-DQBl*0201 haplotype clearly accounts for the previously reported neutral effect for the DRBl*0701 allele in the Caucasian population [2, 29] , a protective effect was shown for the DR7 associated DQAI*0201-DQBI*0303 haplotype, indicating a protective role for the Asp 57+ DQBI*0303 allele.
Next we analysed the homogeneity of the RRs of the different DRB1*04 alleles and of the different DR4-associated DQB1 alleles among the DR4-positive patients and control subjects (Table 4) . It should be mentioned that RRs differ from those presented in Table 2 (for the D QB1 RR) and Table 3 (for the DRB 1"04 RR). Here, the RRs were calculated by comparison with the non-DR4 group (259 diabetic and 358 control chromosomes, respectively). Concerning the DQBI*03 group of alleles, an increased total risk of DQBI*03 was observed in the DR4 positive IDDM group (RR of 4.147). Homogeneity among the separate RRs for the different DQBI*03 alleles within the DR4-positive group could be rejected with a chi-square of 15.251 (1 dr'), corresponding to a p-value of 0.0001. Thus, we can conclude that the risk of DQBI*0302 was significantly increased among DR4 positive IDDM patients. Analogously, we tested the distribution of the DRBI*04 alleles among the DR4-positive group of patients and control subjects (Table 4 ). An increased total risk of DRBI*04 was observed in the DR4 positive IDDM group (RR of 4.147). Homogeneity among the separate RRs for the different DRBI*04 (DRBl*0401 < -> DRB1*0400) alleles within the DR4 positive group could be rejected with a chi-square of 6.699 (1 dr), corresponding to a p-value <0.01. Thus, we can conclude that the risk of DRBl*0401 was significantly increased among DR4 positive IDDM patients. In order to unravel the contribution of DRBI*0401 and DQBl*0302 [32] , we applied a stepwise likelihood-ratio test. Evidence for effects of DQB1 (chi-square 13.398,1 dr) and DRB1 (chisquare 6.527,1 df) was strong. The assumption that both loci act as independent risk factors provided a substantially better explanation of the data (chi-square 6.527, 1 P-values were corrected for the number of alleles or haplotypes tested. The DRB 1"0400 group contains all DRB 1 *04 alleles except DRBI*0401. The DRBl*1300 group contains the DRB1*1301/1305 alleles. All alleles or haplotypes that were not counted at least 10 times in the total (control + IDDM) population were not tested. The DRBI*0301-DRB3 haplotype phase could not be assigned for three control persons that were not included in the analysis. The DRBl*1300-DRB3 haplotype phase could not be assigned for three control persons. ': of the 121 original IDDM DRBI*0401 alleles, five occurred in patients for whom no haplotype could be constructed. ": of the 264 original IDDM non-DRBl*04 DRB1 alleles, five occurred in patients for whom no haplotype could be constructed. "': of the 359 original non-DRBl*04 DRB 1 alleles in the control population, one occurred in a control subject for whom no haplotype could be constructed. RRs were calculated by comparison with the total population -the respective group of alleles for which heterogeneity of the separate alleles or extended haplotypes was tested dr) than the assumption that DRBI*0401 is not a risk factor but simply in linkage disequilibrium with DQB 1"0302 (chi-square 0.110, i dr). The most complex hypothesis, in which both alleles act as risk factors, while a different disequilibrium between both alleles in the IDDM and control population exists provided only a marginally better explanation than the hypothesis in which both alleles act as independent risk factors that are not in disequilibrium (chi-square 1.473, 2 dr). Thus, we can confirm the hypothesis of Sheehy et al. [32] that the DRB1*0401 and DQB1*0302 alleles confer a high risk of developing IDDM and that they act as independent risk factors. P-values were corrected for the number of haplotypes tested. The DRBI*0400 group contains all DRBl*04 alleles except for DRBI*0401. The DRBI*ll00 and DRBl*1300 groups contain the DRBl*1101/1102 and DRBl*1301/1305 alleles, respectively. Probable DRB1-DQA1-DQB1 haplotypes that have not yet been described are indicated by *. All DRB1-DQA1-DQB1 haplotypes that were not counted at least 10 times in the total (control + IDDM) population were not tested. Typing results were not included for seven IDDM patients (DQB1 and DRB typing results were missing for four and three patients, respectively) and one control person (the DRB typing result was missing) (cfr supra). The alleles DQA1*0401/0601 could not be distinguished in one control person and two IDDM patients, encoding DQAl*0201 on the second chromosome. For these persons, only the DQAl*0201 associated baplotype was included in the statistical analysis. Therefore, a total of 406 diabetic and 407 normal chromosomes were compared, n: number of IDDM patients and control subjects, a: number of diabetic and control chromosomes. N. S.: not significant
We also confirmed the previously suggested hypothesis that particular DQA1-DQB1 haplotypes, rather than specific DQA1 or DQB1 alleles, are associated with IDDM [9, 10] . Analysis of the IDDM associated haplotypes showed that the effect of particular increased (susceptibility: S = DQA1ArgS2+ or DQB1ASpS7-) or decreased (protective: P = DQA1 Arg52-or DQB1AspS7+) DQA1 or DQB1 alleles was caused by their association with particular S or P DQB1 or DQA1 alleles, respectively; the effect of the susceptible DQAI*0301 and protective DQAI*0201 alleles appeared to be related to their presence in the DQAI*0301-DQBI*0302 and DQAI*0201-DQBI*0303 haplotypes, respectively.
Analogously, the effect of the susceptible DQBI*0201 and protective DQB1*0301 alleles seemed to be related to their presence in the DQA1*0501-DQBl*0201 and DQAI*0501-DQBI*0301 haplotypes, respectively (Table 5 ). The DQAI*0501 was increased or decreased among the IDDM patient population, depending on the particular DQA1-DQB1 haplotype that was formed and therefore the effect based on its allele frequency was neutralized.
Distribution of DQA1-DQB1 genotypes. Concerning DQB1 genotypes, it was demonstrated previously that homozygosity for non-Asp 57 DQfl chains is positively associated with IDDM [6] [7] [8] . A total of 74.9 % of our Khalil and co-workers [10] originally suggested that IDDM is associated with the combined presence of particular susceptible (S) DQA1 (Arg 52+ ) and susceptible (S) DQB1 (Asp 57-) alleles. In our study, we also detected predisposing effects for particular DQA1 and DQB1 alleles. It has been suggested by Khalil et al. [11] that these factors interact in a specific way. Frequencies of the different HLA-DQ genotypes, according to the number of susceptible (SS) DQA1-DQB1 haplotypes that are encoded in cis and/or trans, among IDDM patients and control subjects, are indicated in Table 6 . The highest risk (RR = 90.667) was observed for those patients, encoding a DQA1-DQB 1 genotype that gives rise to the maximum of SS heterodimers [4] . RR were calculated by comparison with the 0 dose group of per-
Discussion
Using a highly discriminatory DNA typing technique and large populations of IDDM patients and control subjects, we were able to obtain more refined results on the association of IDDM with particular HLA class II alleles, haplotypes and genotypes.
In a first phase we analysed allelic associations for each polymorphic class II locus. We found a significant positive association for Arg 52+ DQA1 and Asp 57-DQB1 alleles, as reported previously [6] [7] [8] 10] . However, we could clearly show heterogeneity among the alleles comprised in each of these groups, only specific alleles being significantly associated. For the DPB1 gene, we found a very significant increase of the rare DPBI*0202 allele among IDDM patients. Analysis of the extended haplotypes for these patients, however, revealed that this association most likely occurred due to linkage disequilibrium of this allele with the DR3 serologic specificity, which positively associates with IDDM. More interesting results were obtained by analysing extended haplotypes and genotypes. As shown in Table 5 , significant association was found for particular DRB-DQA1-DQB1 haplotypes. Specifically for the DR4-related susceptibility haplotype, we showed that it was the combined presence of DRB1*0401-DQA1*0301-DQBl*0302 alleles that was responsible for an increased risk. Moreover, we showed that each of the DRB1*0401 and DQBl*0302 alleles confer an increased risk but also that these alleles act as independent risk factors. For the DR3 specificity, we demonstrated that this effect was restricted to the DRB3*0200 encoding haplotype. The highest predisposing effect was obtained for those DQ genotypes that encode four SS heterodimers (S referring to DQA1 Arg 52+ and DQB1 Asp57-susceptibility alleles). We could not however obtain conclusive evidence of an interactive effect between the susceptible DQA1 and DQB1 alleles, as reported by Khalil et al. [11] .
These data suggest that it isthe specific appearance of particular alleles encoded at the various HLA class II loci that confers susceptibility or protection to IDDM. For the DR4 associated susceptibility we dem-onstrated that both alleles act as independent risk factors. However, how these different loci are involved in the development of IDDM remains unclear, as the nature and the role of possible (auto)antibodies that are responsible for the initiation of the immunologic destruction of pancreatic beta cells remains unclear. Finally, because of the multifactorial nature of IDDM, in which multiple genes and environmental factors are involved, a 100 % HLA-IDDM association could not be obtained in this study. Nevertheless, very significant associations for a restricted number of haplotypes and genotypes were obtained, which could be used in predisposition analyses, particularly in familial cases.
